Parkinson's Disease: An Overview
What is Parkinson’s disease?
Parkinson’s disease (PD) is a chronic, progressive neurological disease that affects nerve cells (neurons) in an area of the brain called the substantia nigra. These cells normally produce dopamine, a chemical (neurotransmitter) that transmits signals between areas in the brain. These signals, when working normally, coordinate smooth and balanced muscle movement. PD, however, causes neurons in the substantia nigra cells to die, leading to a lack of dopamine in the brain. This lack of dopamine occurs especially in the part of the brain known as the basal ganglia. The basal ganglia are responsible for organizing movement commands from other parts of the brain. The loss of dopamine causes PD symptoms.
Who gets PD?
Incidence of PD has reported higher in men than woman, especially after the age of 60. The average age at the onset of symptoms is 61. However, 10 percent of patients are diagnosed before age 40. There is increasing evidence that PD may be inherited.
How is PD diagnosed?
Diagnosing PD is sometimes difficult, since early features may be difficult to assess and may mimic other disorders. For example, tremor may not be apparent as a person is sitting at rest. Posture changes may be mistaken for osteoporosis or simply a sign of aging.
There are currently no sophisticated blood or laboratory tests available to diagnose the disease. Some imaging tests, such as CT (computed tomography) or MRI (magnetic resonance imaging) scans, may be used to rule out other disorders that cause similar symptoms. A detailed neurologic history will be taken. This will include questions about the patient’s symptoms, medications, and the possible exposure to toxins. A doctor may need to observe the patient over time in order to recognize signs of tremor and rigidity. A doctor may try to pair these signs with other characteristic symptoms.
Because the diagnosis is based on the doctor’s examination of the patient, it is very important that the doctor be experienced in evaluating and diagnosing patients with PD. If there is any question whether or not a patient has PD, the patient should see a specialist, preferably a movement disorders-trained neurologist. The treatment decisions made early in the illness can affect the long-term success of the treatment.
Symptoms of PD:
Common symptoms of PD include tremor, or a shaking that begins on one side of the body. In some cases, this tremor is confined to only one body part, such as the hand or foot. However, it may spread as the disease progresses and it can worsen with stress. Tremor rarely disables a patient and often disappears during sleep and when the arm or leg is being moved.
Bradykinesia, another common symptom, is a generalized slowness of movement. Common activities, such as getting dressed or bathing, may take a patient several hours to complete.
Most patients with PD develop some degree of rigidity, or stiffness of limbs. This rigidity is caused by uncontrolled tensing of muscles and results in the patient being unable to move about freely. Also, patients may experience aches or pains from affected muscles.
Balance and coordination problems are additional symptoms of advancing PD. Patients typically develop a forward or backward lean that makes them more likely to fall when bumped. Additionally, a posture is often developed in which the head is bowed and shoulders are slumped (stooped posture).
Other less common symptoms include:
It is important to note that the symptoms of PD can be very different between patients, sometimes making it hard to diagnose. In fact, as many as 25 percent of cases are misdiagnosed.
What treatment options are available?
A variety of medications is available for the treatment of PD symptoms. The most powerful drug for treatment of PD symptoms is levodopa, a chemical found naturally in plants and animals. Nerve cells can use levodopa to make dopamine, which replenishes the low amount in the brain. Levodopa is often used in combination with carbidopa (Sinemet®) to prevent or diminish some of the side effects of the medication. However, there are concerns about the long-term side effects of levodopa, especially the development of involuntary movements (dyskinesias) which can be disabling. Newer medications, such as the dopamine agonists, are much less likely to produce dyskinesias. As a result, most experts recommend against using levodopa early in the course of the disease and to use dopamine agonists instead. If the patient cannot get sufficient relief with the dopamine agonists, particularly the newer generation of dopamine agonists, levodopa/carbidopa (Sinemet) can be added.
Dopamine agonists, such as the newer generation ropinirole (Requip®) and pramipexole (Mirapex®) and the older agent, bromocriptine (Parlodel®), are agonist drugs used to treat PD. These drugs mimic the role of dopamine in the brain and work by stimulating certain parts of the brain and nervous system. They can also be used in combination with levodopa, but are generally less effective in controlling rigidity and bradykinesia. Most experts will use these medications first and only add levodopa if the symptoms cannot be controlled sufficiently.
Another class of drugs used to treat the symptoms of PD is called COMT inhibitors because they block an enzyme that breaks down levodopa and dopamine. Examples of these are tolcapone (Tasmar®) and entacapone (Comtan®). Alone, the medications aren't helpful, but they work well in combination with levodopa. Tolcapone and entacapone slow the body's ability to get rid of levodopa, so it lasts longer and is more consistent. Because they increase the effectiveness of levodopa, tolcapone and entacapone may also increase its side effects, such as involuntary movements. Tolcapone has been associated with liver failure and is thus rarely used. When tolcapone is used, regular blood monitoring for liver damage is required. Other medications include amantadine (Symmetrel®), selegiline (deprenyl), and rasagiline (Azilect®). These drugs can be used in early PD on their own or can be combined with levodopa later in the course of the illness.
There are now a number of safe and effective surgical options available for the treatment of PD. Generally, surgery is only considered when medication cannot provide adequate control.
Deep brain stimulation involves placing an electrode permanently in one of three locations deep in the brain. The electrode is then connected to a type of pacemaker implanted under the skin on the chest. Once activated, the device sends continuous electrical pulses to the targets, blocking the impulses that cause tremors. Deep brain stimulation has many significant advantages. First, it does not require purposeful destruction of any part of the brain and therefore, has few complications. Deep brain stimulation is adjustable and can be changed as the patient's disease or response to medications change. If deep brain stimulation is causing excessive side effects, the stimulator can be turned off and the effects reverse, which is not the case with older destructive surgeries.
Older surgeries required the purposeful destruction of parts of the brain and had a higher risk of complications. They are rarely done today. In pallidotomy, a small section of the brain that is overactive due to PD is permanently destroyed using surgical techniques. This treatment can eliminate rigidity and significantly reduce tremor, bradykinesia, and balance problems. Thalamotomy is a similar procedure where a section of the thalamus, the part of the brain that controls messaging, is destroyed using surgical techniques. This treatment is used only to control tremors and is not generally recommended because of better targets.
Clinical Trial Participation
There are now several treatment options being tested for PD. These include:
medications that slow the progression of disease or alleviate the symptoms of PD
surgical procedures that look into other brain targets or test new devices
non-pharmacological interventions such as exercise, physical, behavioral, and cognitive therapy
Most of these "clinical trials" allow the Parkinson patient to continue with their usual medications while participating in the study. During clinic visits, patients and their caregivers should ask their health care provider if some of these clinical trials are available as an option. Participating may improve their care while contributing to the advancement of PD treatment.
What is the outlook?
Although research is ongoing, to date there is no known cure or preventative measure for PD. It is important to realize that the patient's and physician's efforts should be focused on management of the disease. Through identifying individual symptoms and determining a proper course of action, most people with PD can live enjoyable, fulfilling lives. The good news is that doctors have a much clearer profile of the condition, and are closer than ever to finding a cause—which may help find a cure.
© Copyright 1995-2016 The Cleveland Clinic Foundation. All rights reserved.
Can't find the health information you're looking for?
This information is provided by the Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition. This document was last reviewed on: 10/6/2014...#8525